Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

被引：25

作者：

McGregor, Lisa M. ^{[1
,2
,3
]}

Stewart, Clinton F. ^{[4
]}

Crews, Kristine R. ^{[4
]}

Tagen, Michael ^{[4
]}

Wozniak, Amy ^{[5
]}

Wu, Jianrong ^{[5
]}

McCarville, M. Beth ^{[6
]}

Navid, Fariba ^{[1
,3
]}

Santana, Victor M. ^{[1
,3
]}

Houghton, Peter J. ^{[3
]}

Furman, Wayne L. ^{[1
,3
]}

Galindo, Carlos Rodriguez ^{[1
,3
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA

[3] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Coll Med, Memphis, TN USA

[4] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[5] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA

[6] St Jude Childrens Res Hosp, Dept Radiol, Memphis, TN 38105 USA

来源：

PEDIATRIC BLOOD & CANCER | 2012年 / 58卷 / 03期

基金：

美国国家卫生研究院;

关键词：

adolescent; cephalosporin; child; clinical trial; phase I; irinotecan; ADVANCED COLORECTAL-CANCER; CHILDRENS ONCOLOGY GROUP; SOFT-TISSUE SARCOMA; INDUCED DIARRHEA; PROTRACTED IRINOTECAN; NEUROBLASTOMA XENOGRAFTS; ACTIVATED-CHARCOAL; ANTITUMOR AGENT; SCHEDULES; TRIAL;

D O I：

10.1002/pbc.23075

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Administration of an oral cephalosporin allowed advancement of the dosage of oral irinotecan. This study investigates whether administration of an oral cephalosporin increases the maximum tolerated dose (MTD) of intravenous irinotecan.

引用

页码：372 / 379

页数：8

共 50 条

[1] Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors
Furman, WL
Crews, KR
Billups, C
Wu, JR
Gajjar, AJ
Daw, NC
Patrick, CC
Rodriguez-Galindo, C
Stewart, CF
Dome, JS
Panetta, JC
Houghton, PJ
Santana, VM
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 563 - 570
[2] Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors
R. C. Brennan
W. Furman
S. Mao
J. Wu
D. C. Turner
C. F. Stewart
V. Santana
L. M. McGregor
Cancer Chemotherapy and Pharmacology, 2014, 74 : 1191 - 1198
[3] Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors
Brennan, R. C.
Furman, W.
Mao, S.
Wu, J.
Turner, D. C.
Stewart, C. F.
Santana, V.
McGregor, L. M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1191 - 1198
[4] A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors
Trippett, T. M.
Kuttesch, J.
Herzog, C.
Boklan, J.
Bagatell, R.
Hunger, S.
Arceci, R.
Lu, H.
Langer, C.
Gore, L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[5] A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors.
Furman, WL
Daw, NC
Crews, KR
Stewart, CF
McCarville, B
Santana, VM
Hawkins, D
Rodriguez-Galindo, C
Navid, F
Houghton, PJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 804S - 804S
[6] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
Okada, Keiko
Yamasaki, Kai
Tanaka, Chika
Fujisaki, Hiroyuki
Osugi, Yuko
Hara, Junichi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
[7] Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors
Dugan, Elizabeth
Truax, Roxanne
Meadows, Kellen L.
Blobe, Gerald C.
Morse, Michael A.
Fernando, Nishan H.
Gockerman, Jon P.
Petros, William P.
Hurwitz, Herbert I.
ANTICANCER RESEARCH, 2009, 29 (12) : 5149 - 5153
[8] A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
Sunil Sharma
Joachim Beck
Monica Mita
Sofia Paul
Margaret M. Woo
Margaret Squier
Brian Gadbaw
H. Miles Prince
Investigational New Drugs, 2013, 31 : 974 - 985
[9] A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
Sharma, Sunil
Beck, Joachim
Mita, Monica
Paul, Sofia
Woo, Margaret M.
Squier, Margaret
Gadbaw, Brian
Prince, H. Miles
INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 974 - 985
[10] A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors
Rustum, Y.
Pendyala, L.
Creaven, P.
Ross, M.
Brady, W.
Badmaev, V.
Prey, J.
Fakih, M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →